ORUM (475830) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ORUM (475830) has a cash flow conversion efficiency ratio of -0.045x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-7.31 Billion ≈ $-4.96 Million USD) by net assets (₩161.79 Billion ≈ $109.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ORUM defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
ORUM - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how ORUM's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ORUM Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ORUM ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sentient Brands Holdings Inc
NASDAQ:SNBHD
|
0.019x |
|
Vantex Resources Ltd
V:VAX
|
-0.172x |
|
Wyld Networks AB
ST:WYLD
|
-2.557x |
|
Angling Direct PLC
LSE:ANG
|
0.059x |
|
Ontrak Inc
NASDAQ:OTRK
|
-0.586x |
|
PETREL RESOURCES (PQ4.SG)
STU:PQ4
|
0.088x |
|
Corcel PLC
LSE:CRCL
|
-0.708x |
|
Lendinvest PLC
LSE:LINV
|
0.135x |
Annual Cash Flow Conversion Efficiency for ORUM (2022–2024)
The table below shows the annual cash flow conversion efficiency of ORUM from 2022 to 2024. For the full company profile with market capitalisation and key ratios, see ORUM (475830) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩121.76 Billion ≈ $82.52 Million |
₩-11.28 Billion ≈ $-7.65 Million |
-0.093x | +94.48% |
| 2023-12-31 | ₩-56.18 Billion ≈ $-38.07 Million |
₩94.24 Billion ≈ $63.87 Million |
-1.678x | -620.35% |
| 2022-12-31 | ₩-127.46 Billion ≈ $-86.38 Million |
₩-41.09 Billion ≈ $-27.85 Million |
0.322x | -- |
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, wh… Read more